SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending following news that the U.S. government is considering taking a stake in the company to secure rare earth elements. The community views this as a potential catalyst for significant growth, drawing comparisons to other rare earth plays. Discussions revolve around the importance of rare earth minerals for national security and the potential impact of government investment.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors discuss its massive surge, with some questioning the valuation relative to revenue and others pointing to the potential of the quantum computing sector. Community members are debating whether the stock is overhyped, a potential short squeeze, or a long-term investment in a revolutionary technology, while also watching for potential offerings.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss its chart patterns, particularly a potential cup and handle formation, and anticipate upcoming catalysts. Community members are weighing the possibility of government funding and regulatory milestones while debating the stock's potential price targets. Sentiment appears bullish, with some anticipating a significant breakout soon, especially compared to other stocks in the sector that have seen larger gains recently.

The project was established through the BAGS.FM app which is platform that allows projects to create projects with cause, our project directly generates trading fees and processes them through the BAGS app to directly donate towards the official Dolphin Project - We're the first crypto token to passively provide donations and change to acquatic life and have already raised $8,000 towards providing sactuary for captured dolphins.

Dolphin

Dolphin Crypto ($DOLPHIN) is trending as social media buzz points to a potential breakout, with many highlighting its bullish chart and strong liquidity. The community is actively discussing entry points via Phantom Wallet and anticipating a significant price movement. Others urge caution, referencing the token's market cap and potential for volatility within the broader crypto space.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amidst reports of security flaws in its battlefield communications technology, though the company claims the issues are outdated and inaccurate. The community is debating the validity of the reports and their impact on Palantir's contracts, with some viewing the dip as a buying opportunity. Discussions also involve the company's valuation and broader market conditions.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community anticipates a potential surge, fueled by its recent listing on Robinhood and ongoing discussions about its utility, ecosystem, and meme status. Some community members are expressing excitement about a potential 'banana zone' and drawing comparisons to past meme coin successes, while others highlight its strong community and potential for significant gains in the coming altseason. The recent DAO vote to invest in RICE AI token is also generating buzz.

Codatta

Codatta ($XNY) is gaining attention, with community members discussing its potential breakout and identifying key support levels. The anticipated launch of on-chain fingerprint verification is generating buzz, alongside discussions of its chart patterns and potential for new highs. Bullish sentiment appears to be building around its utility and recent performance against broader market trends.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to unusual options activity and anticipation surrounding an upcoming PDUFA date, with investors speculating on potential label expansion approval. The community is actively discussing the company's valuation, potential buyout scenarios, and revenue forecasts. Some traders point out technical patterns and potential manipulation in the stock's price action.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community emphasizes its cultural significance and likens it to Bitcoin. There's active discussion around its potential and some speculation about future developments. Community members are sharing links to the project's website and Dexscreener.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. ($ROOT) is trending amid discussions about its growth potential, partnerships, and recent stock performance. Community members are debating the company's valuation, with some citing a low forward P/E while others point to insider selling and Q3 loss expectations, creating opposing viewpoints.  The stock's potential for a short squeeze and comparisons to competitors like Lemonade ($LMND) are also fueling active discussions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Petros Pharmaceuticals sank to an all-time low on Wednesday after the company enacted a 1-for-25 reverse stock split, triggering a wave of retail investor chatter and raising fresh concerns about its Nasdaq listing status.The split, which became effective after markets closed Wednesday, aimed to lift Petros’ share price above Nasdaq’s $1 minimum bid requirement.&nbsp;While the maneuver shrank the company’s outstanding share count from roughly 53.5 million to about 2.14 million, it failed to stabilize investor sentiment.&nbsp;Shares tumbled more than 30% intraday Thursday, hitting a split-adjusted low of $0.012 — the stock’s lowest level since its 2020 debut.Despite the steep sell-off, sentiment among retail investors turned “extremely bullish” on Stocktwits amid “extremely high” message volume.One user said, “Given the incentive to exercise at no cost, they may use the remaining shares to drive the price down further,” adding that volume needed to hit at least 30 million before considering a position.&nbsp;<stembedurl>https://stocktwits.com/basijedal/message/613198834</stembedurl>Another said the reverse split “might actually be positive,” citing the post-split price as potentially attractive to speculators. “It probably will still be volatile and could go up,” they added.<stembedurl>https://stocktwits.com/1Black/message/613194524</stembedurl>The steep decline comes as Petros continues to face the risk of delisting from the Nasdaq Capital Market, after previously receiving a noncompliance notice related to minimum stockholders' equity requirements.In parallel, the company is pivoting from its legacy men’s health products toward regulatory-aligned digital health solutions.&nbsp;Petros is developing a software-as-a-medical-device platform that leverages AI and big data to assist pharmaceutical companies with converting prescription drugs to over-the-counter status.&nbsp;Management positioned this strategy as well-timed following President Trump’s April 15 executive order titled&nbsp;“Lowering Drug Prices by Once Again Putting Americans First”—a policy Petros says supports its market transition.“This Executive Order supports the notion that the under-insured and the American population at large will benefit from expanded access to certain drugs,” said Chief Commercial Officer Fady Boctor.&nbsp;He added that Petros’ platform could unlock partnerships with pharmaceutical firms aiming to extend their product lifecycles and reduce drug prices.But questions remain about the company’s financial health.&nbsp;For the year ended Dec. 31, 2024, Petros reported revenue of $5.11 million, down from $5.82 million in 2023.&nbsp;Net losses widened to $14.32 million from $8.16 million, even as loss per share narrowed to $3.34 from $6.35 due to a higher share count.Petros shares have tumbled over 99.9% year-to-date, far underperforming the Dow Jones, down 4.1%, the S&amp;P 500, down 5.1%, and the Nasdaq, down 1.6%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange during morning trading on April 30, 2025 in New York City. (Photo by Michael M. Santiago/Getty Images)

Petros Pharma Stock Plunges To Record Low On 1-For-25 Reverse Split, But Retail Optimism Lingers

Petros Pharmaceuticals hit an all-time low after a 1-for-25 reverse stock split, drawing bullish retail chatter even as delisting risks and mounting losses weighed on the stock.

Equity

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI Research Report) yesterday. The company's shares closed ye...

EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says

Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the...

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56...

Petros Pharmaceuticals (NASDAQ:PTPI) & Liberty Health Sciences (OTCMKTS:LHSIF) Critical Review

Liberty Health Sciences (OTCMKTS:LHSIF - Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will...

Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC...

Petros Pharmaceuticals enters AI-licensing agreement with software provider

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch

FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Petros Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PTPI
Petros Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PTPI News

PTPI Petros Pharmaceuticals Inc